Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial

To compare, in a double‐blind, randomized, multi‐national study, 52‐ or 78‐week treatment with basal insulin peglispro or insulin glargine, added to pre‐study oral antihyperglycaemic medications, in insulin‐naïve adults with type 2 diabetes.

[1]  A. Chang,et al.  Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5 , 2015, Diabetes Care.

[2]  G. Shulman,et al.  Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids , 2015, Proceedings of the National Academy of Sciences.

[3]  Junxiang Luo,et al.  Estimation of group means when adjusting for covariates in generalized linear models , 2015, Pharmaceutical statistics.

[4]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[5]  P. Home,et al.  Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508 , 2014, Diabetes Care.

[6]  S. Mudaliar,et al.  Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects , 2014, Diabetes Care.

[7]  P. Home,et al.  Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? , 2014, Diabetes Care.

[8]  M. Davidson.  Insulin Analogs—Is There a Compelling Case to Use Them? No! , 2014, Diabetes Care.

[9]  T. Heise,et al.  Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus , 2014, Diabetes, obesity & metabolism.

[10]  D. Owens,et al.  Basal insulin analogues in the management of diabetes mellitus: what progress have we made? , 2014, Diabetes/metabolism research and reviews.

[11]  J. M. Beals,et al.  Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism , 2014, Diabetes.

[12]  D. Russell-Jones,et al.  Hepatoselectivity and the evolution of insulin , 2014, Diabetes, obesity & metabolism.

[13]  Junxiang Luo,et al.  The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: a systematic analysis of 15 diabetes clinical trials. , 2013, Diabetes technology & therapeutics.

[14]  Junxiang Luo,et al.  Analysis of hypoglycemic events using negative binomial models , 2013, Pharmaceutical statistics.

[15]  R. Adamson,et al.  Tonic regulation of vascular permeability , 2013, Acta physiologica.

[16]  N. Skolnik,et al.  Management of Hyperglycemia in Type 2 Diabetes , 2012 .

[17]  A. Farmer,et al.  Three-year efficacy of complex insulin regimens in type 2 diabetes. , 2009, The New England journal of medicine.

[18]  P. Home,et al.  Management of type 2 diabetes: NICE guidelines. , 2009, Clinical medicine.

[19]  K. Reynolds,et al.  Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta‐analysis of randomized controlled trials , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[20]  A. Tamhane,et al.  A note on tree gatekeeping procedures in clinical trials , 2008, Statistics in medicine.

[21]  Martin Adiels,et al.  Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[22]  J. Rosenstock,et al.  A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes , 2008, Diabetologia.

[23]  M. Davies,et al.  Initiate Insulin by Aggressive Titration and Education (INITIATE) , 2007, Diabetes Care.

[24]  A. Berghold,et al.  Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. , 2007, The Cochrane database of systematic reviews.

[25]  A. Häkkinen,et al.  Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[26]  M. Buchfelder,et al.  Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. , 2007, European journal of endocrinology.

[27]  P. Raskin.  Initiation of insulin therapy in patients with type 2 diabetes failing oral therapy: response to Mikhail and Cope and to Janka. , 2005, Diabetes care.

[28]  J. Rosenstock,et al.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. , 2003, Diabetes care.

[29]  Filip Braet,et al.  Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review , 2002, Comparative hepatology.

[30]  Robert J. Anderson,et al.  The Veterans Affairs Implantable Insulin Pump Study: Effect on cardiovascular risk factors , 1998, Diabetes Care.

[31]  K. Alberti,et al.  Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus. , 1989, Metabolism: clinical and experimental.